Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Neolignans isolated from twigs of Nectandra leucantha Ness & Mart (Lauraceae) displayed in vitro antileishmanial activity

Full text
Grecco, Simone S. [1, 2] ; Costa-Silva, Thais A. [1] ; Sousa, Fernanda S. [3] ; Cargnelutti, Stefano B. [3] ; Umehara, Eric [1] ; Mendonca, Poliana S. [1] ; Tempone, Andre G. [4] ; Lago, Joao Henrique G. [1]
Total Authors: 8
[1] Fed Univ ABC UFBC, Ctr Nat Sci & Humanities, Ave Estados 5001, BR-09210580 Santo Andre, SP - Brazil
[2] Anhanguera Univ Sao Paulo, Biotechnol & Innovat Hlth Postgrad Program, Sao Paulo, SP - Brazil
[3] Fed Univ Sao Paulo UNIFESP, Inst Environm Chem & Pharmaceut Sci, Diadema, SP - Brazil
[4] Adolfo Lutz Inst, Ctr Parasitol & Mycol, Sao Paulo, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Journal of Venomous Animals and Toxins including Tropical Diseases; v. 24, SEP 27 2018.
Web of Science Citations: 0

Background: The therapeutic arsenal for the treatment of Leishmaniasis is limited and includes toxic compounds (antimonials, amphotericin B, pentamidine and miltefosine). Given these aspects, the search for new compounds based on floristic biodiversity is crucial. In the present work, we report the isolation, characterization and antileishmanial activity of six related neolignans (1-6) of bioactive extract from Nectandra leucantha (Lauraceae) twigs. Methods: Dried and powdered twigs of N. leucantha were exhaustively extracted using n-hexane. The crude extract was dereplicated by HPLC/HRESIMS and subjected to column chromatography to yield pure compounds 1-6. Their chemical structures were identified via NMR and comparison of obtained data with those previously published in the literature. Biological assays of compounds 1-6 and their respective monomers (eugenol and methyleugenol) were performed using promastigote and amastigote forms of Leishmania (L) infantum. Results: Dereplication procedures followed by chemical characterization of isolated compounds by NMR enabled the identification of related neolignans 1-6. Neolignans 2, 4 and 6 showed potential against amastigote forms of L (L) infantum (EC50 values of 57.9, 67.7 and 13.7 mu M, respectively), while compounds 1 and 3 were inactive. As neolignans 2-4 are chemically related, it may be suggested that the presence of the methoxyl group at C4 constitutes an important structural aspect to increase antileishmanial potential against amastigote forms. Compound 6, which consists of a methylated derivative of compound 5 (inactive) showed antileishmanial activity similar to that of the standard drug miltefosine (EC50 = 16.9 mu M) but with reduced toxicity (SI = 14.6 and 72, respectively). Finally, two related monomers, eugenol and methyleugenol, were also tested and did not display activity, suggesting that the formation of dimeric compounds by oxidative coupling is crucial for antiparasitic activity of dimeric compounds 2, 4 and 6. Conclusion: This study highlights compound 6 against L. (L) infantum amastigotes as a scaffold for future design of new compounds for drug treatment of visceral leishmaniasis. (AU)

FAPESP's process: 18/07885-1 - Biomolecules from plant species of remnant areas of the Atlantic Forest and Cerrado to treat neglected tropical diseases - chemical and pharmacological aspects
Grantee:João Henrique Ghilardi Lago
Support type: BIOTA-FAPESP Program - Regular Research Grants
FAPESP's process: 15/23403-9 - Rational pre-clinical study of new drug candidates against neglected protozoan diseases using pharmacokinetic approaches
Grantee:André Gustavo Tempone Cardoso
Support type: Regular Research Grants